Hormone shots plus vaccine aims to supercharge immune attack on prostate cancer

NCT ID NCT06100705

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This phase II trial tests whether adding bipolar androgen therapy (cycles of testosterone) to the standard Sipuleucel-T vaccine can boost the immune response in men with metastatic castration-resistant prostate cancer. About 26 participants will receive both treatments, and researchers will measure immune cell activity in the blood. The goal is to see if the combination makes the vaccine work better against the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Testosterone Cypionate and Sipuleucel-T (Provenge)
What this could lead to: If it works, this combination could improve the immune system's ability to fight prostate cancer, potentially slowing disease progression.
What could go wrong: This is a small, early-phase trial with only 26 participants, so results may not apply to everyone. The treatment may not boost immunity enough to help, and testosterone therapy can cause side effects like hormone fluctuations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.